Tango Therapeutics (TNGX) Current Deferred Revenue (2020 - 2025)

Tango Therapeutics' Current Deferred Revenue history runs 6 years deep, the most recent figure standing at $23.4 million for Q2 2025.

• On a quarterly basis, Current Deferred Revenue fell 1.24% year-over-year to $23.4 million in Q2 2025; TTM through Jun 2025 was $23.4 million, a 1.24% decrease from a year earlier, with the FY2024 full-year figure at $17.6 million, down 31.37% from the prior year.
• Current Deferred Revenue rose to $23.4 million in Q2 2025 per TNGX's latest filing, from $19.5 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $34.0 million in Q1 2023 and bottomed at $15.6 million in Q3 2024.
• The 5-year median for Current Deferred Revenue is $25.8 million (2021), against an average of $25.7 million.
• Across the five-year window, Current Deferred Revenue surged 35.91% in 2023 and slumped 42.37% in 2024, its largest moves.
• Year by year, Current Deferred Revenue stood at $26.0 million in 2021, then gained by 22.17% to $31.8 million in 2022, then decreased by 19.26% to $25.7 million in 2023, then plunged by 31.37% to $17.6 million in 2024, then jumped by 32.67% to $23.4 million in 2025.
• Per Business Quant, the three latest TNGX Current Deferred Revenue figures stand at $23.4 million (Q2 2025), $19.5 million (Q1 2025), and $17.6 million (Q4 2024).